Definitive experimental evidence from mouse cancer models and strong correlative clinical data gave rise to the Cancer Immunoediting concept that explains the dual host-protective and tumor-promoting actions of immunity on developing cancers. Tumor-specific neoantigens can serve as targets of spontaneously arising adaptive immunity to cancer and thereby determine the ultimate fate of developing tumors. Tumor-specific neoantigens can also function as optimal targets of cancer immunotherapy against established tumors. These antigens are derived from nonsynonymous mutations that occur during cellular transformation and, because they are foreign to the host genome, are not subject to central tolerance. In this review, we summarize the experimental evidence indicating that cancer neoantigens are the source of both spontaneously occurring and therapeutically induced immune responses against cancer. We also review the advances in genomics, bioinformatics, and cancer immunotherapy that have facilitated identification of neoantigens and have moved personalized cancer immunotherapies into clinical trials, with the promise of providing more specific, safer, more effective, and perhaps even more generalizable treatments to cancer patients than current immunotherapies.

Original languageEnglish
Title of host publicationTumor Immunology, 2016
EditorsRobert D. Schreiber
PublisherAcademic Press Inc.
Number of pages50
ISBN (Print)9780128051566
StatePublished - 2016

Publication series

NameAdvances in Immunology
ISSN (Print)0065-2776
ISSN (Electronic)1557-8445


  • Cancer Immunoediting
  • Cancer immunotherapy
  • Checkpoint blockade immunotherapy
  • Neoantigens
  • Tumor-specific mutant antigens


Dive into the research topics of 'The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer'. Together they form a unique fingerprint.

Cite this